Comparative Pharmacology
Head-to-head clinical analysis: UROVIST CYSTO versus UROVIST MEGLUMINE DIU CT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UROVIST CYSTO versus UROVIST MEGLUMINE DIU CT.
UROVIST CYSTO vs UROVIST MEGLUMINE DIU/CT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urovist Cysto is a radiocontrast agent containing diatrizoate meglumine and diatrizoate sodium. It provides radiographic visualization of the urinary tract by attenuating X-rays due to its iodine content. It is not systemically absorbed when used intravesically; local contrast enhancement occurs through physical properties.
Urovist Meglumine DIU/CT is a contrast agent containing meglumine diatrizoate, an ionic monomeric iodinated radiopaque medium. It attenuates X-rays, enhancing vascular and tissue contrast during imaging. The diatrizoate ion increases plasma osmolality, potentially causing vasodilation and hemodynamic effects.
Instillation of 50 mL of a 0.3% solution intravesically, retained for 10 minutes, for cystography.
Intravenous administration: 100-200 mL of a 30% solution (containing 30% meglumine diatrizoate) infused over 10-30 minutes for CT imaging. Repeated doses may be given up to a maximum total dose equivalent to 4.0 mL/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life 1–2 hours in patients with normal renal function. Prolonged to >20 hours with severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion as unchanged drug (approximately 85-90% within 24 hours); minor biliary/fecal elimination (<5%).
Renal: >95% unchanged within 24 hours by glomerular filtration. Biliary/fecal: <5%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent